in

White House scraps Dr. Heidi Overton FDA pick after Hill revolt

The White House quietly pulled the nomination of Dr. Heidi Overton to lead the Food and Drug Administration this week, just before the Senate Health, Education, Labor and Pensions Committee was set to vote. The administration says the move came because Overton didn’t have the votes on the Hill, and officials say they’ll back Health and Human Services Secretary Robert F. Kennedy Jr.’s agenda as they search for a new FDA leader.

White House says Overton lacked support — and the timing tells the story

The decision to withdraw Heidi Overton’s nomination came on the eve of a HELP Committee vote, after the White House concluded she did not have the necessary congressional backing. A senior administration official told Axios that “FDA nominee Heidi Overton lacks the support on the Hill to move forward with her confirmation” and that the White House wants to “go in a new direction” in line with Secretary Kennedy’s Make America Healthy Again vision. Overton had been nominated in August and was serving as deputy director on the White House Domestic Policy Council, but the math in the committee was unforgiving: Republicans held a one-seat edge and she would have needed nearly unanimous GOP support to advance.

Why Republicans and Democrats both balked

Opposition to Overton wasn’t limited to Democrats. Senator Bill Cassidy, chair of the HELP Committee, publicly said Overton’s role in the administration’s push to change childhood vaccine recommendations was “almost disqualifying.” Other senators raised concerns about her record on vaping policy, reproductive‑health matters tied to mifepristone, and whether she really belonged to the Make America Healthy Again movement’s inner circle. Overton did tell senators in her hearing that FDA‑approved drugs that meet statutory standards are “safe and effective,” and promised to follow the agency’s legal safety-and-efficacy rules. That didn’t seem to be enough to quiet the broader doubts.

What this means for the FDA and the administration

The FDA remains under Acting Commissioner Kyle Diamantas, and the agency has seen a steady churn of leaders since Marty Makary resigned. The White House now has to pick again — either another nominee who can win confirmation or a stopgap acting boss. The administration’s statement about supporting Secretary Kennedy’s agenda signals it wants an FDA chief who fits that populist, health-policy makeover. But politics matters: if your candidate can’t get a single committee vote from your own side, that’s a vetting problem, not just a personnel one.

Political fallout and what comes next

This withdrawal is more than a single failed pick. It highlights a wider problem for an administration that promises big changes to health policy but struggles to deliver confirmations. Senate dynamics will decide the next moves. Republicans on the HELP Committee hold leverage now, and the White House will either pick someone less controversial or invite another round of public skirmishes. For conservatives who want to see conservative wins at the FDA, the lesson is blunt: back a candidate who can win votes, not just headlines. The search for the next nominee starts now — and the clock is already ticking.

Written by admin

Leave a Reply

Your email address will not be published. Required fields are marked *

Former President Biden Says Newsom Stepped Aside to Avoid Walkout

Former President Biden Says Newsom Stepped Aside to Avoid Walkout

Optimizely Supply-Chain Hack Infects 178 Sites, Targets iPhones

Optimizely Supply-Chain Hack Infects 178 Sites, Targets iPhones